A prospective study of antimullerian hormone as a potential predictor of chemotherapy induced menopause

A prospective study of antimullerian hormone (AMH) as a potential predictor of chemotherapy induced menopause in premenopausal women age 18-45 undergoing curative intent chemotherapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611000613909

Enrollment

Registered

2011-06-15

Start date

2011-06-21

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to investigate whether antimullerian hormone levels can be used to predict which patients will develop menopause following chemotherapy. Chemotherapy is known to induce menopause in some patients however at this point we do not have a test which allows us to give a patient their individual risk of developing menopause post chemotherapy. The hypothesis for our study is that patients with lower antimullerian hormone levels prior to the start of chemotherapy will be more likely to develop chemotherapy induced menopause.

Interventions

This study will be investigating the association between antimullerian hormone levels (AMH) and chemotherapy induced menopause. Antimullerian hormone levels will be assessed at baseline, at the second cycle of chemotherapy, third cycle of chemotherapy, final cycle of chemotherapy and then 12 months post completion of chemotherapy. Menstruation will be recorded throughout this period as an indicator of menopausal status. The total period of observation for each participant will be between 16-1

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

*Female planned for first line gonadotoxic chemotherapy defined as chemotherapy associated with >25% rates of ovarian failure. Examples of appropriate chemotherapy regimens includes: FAC, FEC, AC, AC-T, , FEC-D, TAC, TC, R-CHOP, ABVD and BEACOPP * Cancer treated with curative intent * Age 18-45 * Premenopausal defined as at least 2 menstrual cycles within 180 days of study enrolment or if recently ceased oral or implantable contraception gonadotropin levels within premenopausal range * Able to provide informed consent

Exclusion criteria

* planned for long term GNRH analogue post chemotherapy * hysterectomy and/or bilateral oophorectomy prior to commencement of chemotherapy * pregnant at time of enrolment

Outcome results